Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Biomarker Study of Talazoparib Monotherapy in Recurrent or Metastatic Solid Tumors
2014-004011-37Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talazoparib in breast cancer, ovarian cancer and Non-hematologic malignancy, sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Objective response rate (ORR) by RECIST 1.1. Started Jun 2015; status: completed.
02
Drugs
talazoparib
03
Conditions
breast cancerovarian cancerNon-hematologic malignancy
Beyond the preview
Go deeper on 2014-004011-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004011-37.